MX2020011884A - Metodo para la xeno-generacion libre de una poblacion de hmpc. - Google Patents

Metodo para la xeno-generacion libre de una poblacion de hmpc.

Info

Publication number
MX2020011884A
MX2020011884A MX2020011884A MX2020011884A MX2020011884A MX 2020011884 A MX2020011884 A MX 2020011884A MX 2020011884 A MX2020011884 A MX 2020011884A MX 2020011884 A MX2020011884 A MX 2020011884A MX 2020011884 A MX2020011884 A MX 2020011884A
Authority
MX
Mexico
Prior art keywords
population
hmpc
xeno
free generation
skeletal muscle
Prior art date
Application number
MX2020011884A
Other languages
English (en)
Inventor
Daniel Eberli
Deana Mohr
Souzan Salemi
Fahd Azzabi Zouraq
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2020011884A publication Critical patent/MX2020011884A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con un método para generar una población de células precursoras de músculo humano derivadas de músculo esquelético. Para este fin, se utiliza un medio de crecimiento celular especializado sin FBS. La invención se relaciona además con una composición que comprende esta población de hMPC para utilizarse como un medicamento, en especial en el tratamiento de la disfunción del músculo esquelético.
MX2020011884A 2018-05-08 2019-05-06 Metodo para la xeno-generacion libre de una poblacion de hmpc. MX2020011884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18171162 2018-05-08
PCT/EP2019/061561 WO2019215090A1 (en) 2018-05-08 2019-05-06 Method for xeno-free generation of a population of hmpc

Publications (1)

Publication Number Publication Date
MX2020011884A true MX2020011884A (es) 2021-01-20

Family

ID=62142966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011884A MX2020011884A (es) 2018-05-08 2019-05-06 Metodo para la xeno-generacion libre de una poblacion de hmpc.

Country Status (10)

Country Link
US (1) US20210244770A1 (es)
EP (1) EP3790957A1 (es)
JP (2) JP2021522805A (es)
KR (1) KR20210008009A (es)
AU (1) AU2019266916A1 (es)
BR (1) BR112020022667A2 (es)
CA (1) CA3098775A1 (es)
IL (1) IL287353A (es)
MX (1) MX2020011884A (es)
WO (1) WO2019215090A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117025503A (zh) * 2022-05-10 2023-11-10 上海赛立维生物科技有限公司 肝内胆管前体样细胞、细胞制剂及制备方法和应用
WO2024047234A1 (en) 2022-09-02 2024-03-07 Universität Zürich Injection device
WO2024075145A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 新規な歯髄幹細胞集団
WO2024075675A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 新規な歯髄幹細胞集団
WO2024115761A1 (en) * 2022-12-01 2024-06-06 Universität Zürich Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
EP2118271B1 (en) * 2007-01-11 2018-04-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
US20140227233A1 (en) 2013-01-29 2014-08-14 University Hospitals Cleveland Medical Center Treatment of Urinary Incontinence with Regenerative Glue
WO2016138289A1 (en) 2015-02-27 2016-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods of generating cells of the smooth muscle lineage and uses thereof

Also Published As

Publication number Publication date
US20210244770A1 (en) 2021-08-12
BR112020022667A2 (pt) 2021-02-09
AU2019266916A1 (en) 2020-10-22
WO2019215090A1 (en) 2019-11-14
EP3790957A1 (en) 2021-03-17
CA3098775A1 (en) 2019-11-14
IL287353A (en) 2021-12-01
JP2024028920A (ja) 2024-03-05
JP2021522805A (ja) 2021-09-02
KR20210008009A (ko) 2021-01-20

Similar Documents

Publication Publication Date Title
MX2020011884A (es) Metodo para la xeno-generacion libre de una poblacion de hmpc.
WO2016182959A8 (en) Optimized crispr/cas9 systems and methods for gene editing in stem cells
PH12018500371A1 (en) Clinical formulations
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
MX2020005503A (es) Metodos para activar, modificar y expandir linfocitos t gamma delta para el tratamiento del cancer y de neoplasias malignas relacionadas.
SG10201906070XA (en) Compositions and methods for high efficiency in vivo genome editing
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
MX342995B (es) Métodos de generar células asesinas naturales.
MX2023003296A (es) Generacion de lineas de cardiomiocitos auriculares y ventriculares a partir de celulas madre pluripotentes humanas.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
MX2021008772A (es) Composiciones y metodos para la estimulacion de celulas natural killer.
MX2021004579A (es) Métodos para trasplante de células madre hematopoyéticas alogénicas.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
NZ755744A (en) Peptides and methods for the treatment of diabetes
MY191776A (en) Method for preparing electrocompetent yeast cells, and method for using said cells
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
MX2021011608A (es) Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
SG11201806445UA (en) Cell mass, cell structure, and three-dimensional tissue body
MX2017011656A (es) Material de implante compuesto.
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
AU2020344620A8 (en) Implant comprising first and second sets of pillars for attaching a tendon or ligament to a hard tissue
WO2015162306A8 (de) Verfahren zur oberflächenbehandlung eines biokorrodierbaren implantats
SG10201806618VA (en) Power-generation system having a combined heat and power plant and method for power generation
JOP20190279A1 (ar) الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة